Back to Article
Efficacy and Safety of Long-Term Anticoagulation Therapy with Direct Oral Anticoagulants versus Vitamin K Antagonist in Patients with Cerebral Venous Thrombosis
Open Journal of Medical Sciences
| Vol 3, Issue 1
Table 1. Characteristics of studies included in the review
| Study (Year of Publication) | Study Design | Sample Size | Location | Age, years | Female (%) | Duration of Anticoagulation | Follow-up Duration |
| Ferro et al (2019) | Randomized Controlled Trial | 60 Warfarin60 Dabigatran | Multicenter | 45,2 + 13.8 | 33 (55%)33 (55%) | 5.15 months | 3 months |
| Connor et al (2020) | Randomized Controlled Trial | 41 Standard Anticoagulation73 Rivaroxaban | Multicenter | Pediatric Population (<18 years) | 18 (44%)27 (37%) | 3 months | 3 months |
| Khorvash et al (2021) | Randomized Controlled Trial | 25 Warfarin25 Rivaroxaban | Iran | 40.76 + 11.7241.20 + 11.35 | 19 (76%)17 (68%) | 3 months | 6 months |
| Masqood et al (2021) | Randomized Controlled Trial | 24 Warfarin21 Rivaroxaban | Pakistan | 27 years26 years | 19 (79%)18 (86%) | 3-12 months | 12 months |